NTT-LTD.
NTT Ltd., a leading IT infrastructure and services company, today announced the launch of Edge-as-a-Service, a managed edge compute platform that gives enterprises the ability to deploy quickly, manage and monitor applications closer to the edge.
NTT and VMware, in collaboration with Intel, are partnering to innovate on edge-focused solutions and services. NTT uses VMware’s Edge Compute Stack to power its new Edge-as-a-Service offering. Additionally, VMware is adopting NTT’s Private 5G technologies as part of its edge solution. The companies will jointly market the offering through coordinated co-innovation, sales, and business development.
NTT’s Edge-as-a-Service offering is a globally available integrated solution that accelerates business process automation. It delivers near-zero latency for enterprise applications at the network edge, optimizing costs and boosting end-user experiences in a secure environment.
NTT’s Edge-as-a-Service offering, powered by VMware’s Edge Compute Stack, includes Private 5G connectivity and will be delivered by NTT across its global footprint running on Intel network and edge technology.
“Combining Edge and Private 5G is a game changer for our customers and the entire industry, and we are making it available today,” said Shahid Ahmed, Group EVP, New Ventures and Innovation CEO, NTT. “The combination of NTT and VMware’s Edge Compute Stack and Private 5G delivers a unique solution that will drive powerful outcomes for enterprises eager to optimize the performance and cost efficiencies of critical applications at the network edge. Minimum latency, maximum processing power, and global coverage are exactly what enterprises need to accelerate their unique digital transformation journeys.”
As factories increase their reliance on robotics, vehicles become autonomous, and manufacturers move to omnichannel models, there is a greater need for distributed compute processing power and data storage with near-instantaneous response times. VMware’s secure application development, resource management automation, and real-time processing capabilities combined with NTT’s multi-cloud and edge platforms, creates a fully integrated Edge+Private 5G managed service. VMware and NTT’s innovative offering resides closer to where the data is generated or collected, enabling enterprises to access and react to information instantaneously.
This solution, which leverages seamless multi-cloud and multi-tenant connectivity, combined with NTT’s capabilities in network segmentation, and expertise with movement from private to public 5G, provides critical benefits for multiple industries, including manufacturing, retail, logistics, and entertainment.
“Enterprises are increasingly distributed — from the digital architecture they rely on to the human workforce that powers their business daily. This has spurred a sea change across every industry, altering where data is produced, delivered, and consumed,” said Sanjay Uppal, senior vice president and general manager, service provider, and edge business unit, VMware. “Bringing VMware’s Edge Compute Stack to NTT’s Edge-as-a-Service will enable our mutual customers to build, run, manage, connect and better protect edge-native applications at the Near and Far Edge while leveraging consistent infrastructure and operations with the power of edge computing.”
NTT’s Edge-as-a-Service platform was developed to help secure, optimize and simplify organizations’ digital transformation journeys. Edge-as-a-Service is part of NTT’s Managed Service portfolio, which includes Network-as-a-Service and Multi-Cloud-as-a-Service, all designed for enterprises to focus on their core business.
To learn more, attend the Modernize and Monetize with VMware Multi-Cloud Edge Solutions – Session 2432 and Managed VMware Edge Compute Stack and Edge services delivered by NTT – Session 2234 at VMware Explore on Tuesday August 30th.
About NTT Ltd.
NTT Ltd. is a leading IT infrastructure and services company. With revenues of over USD 10 billion, we operate in more than 200 countries and regions and serve 5,000 clients across multiple industries. Through technology and innovation, we deliver a secure and connected future that empowers our people, clients and communities. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multi-cloud environments, and innovate at the edge of their IT environments, where networks, cloud and applications converge. On the journey towards a software-defined future, we support organizations with platform-delivered infrastructure services. As part of the global NTT Corporation, we serve 65% of the Fortune Global 500 and 80% of the Fortune Global 100. We enable a connected future. Visit us at services.global.ntt
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom